Skip to main content
. 2021 Feb 2;13(3):572. doi: 10.3390/cancers13030572

Figure 1.

Figure 1

EFS and OS by (A) prospective International Neuroblastoma Staging System (INSS) as outlined in the A-NB94 trial; (B) post hoc grouping according to the International Neuroblastoma Risk Group (INRG) Staging System; (C) presence or absence of segmental chromosomal aberrations (SCAs); (D) effect of MYCN amplification (MNA) status in INSS stage 4 patients only.